Hiroki Shirai
Overview
Explore the profile of Hiroki Shirai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
644
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kamoshita M, Shirai H, Nakamura H, Kishimoto T, Hatanaka Y, Mashiko D, et al.
Sci Rep
. 2025 Jan;
15(1):625.
PMID: 39753886
Spermatogenesis is one of the most complex processes of cell differentiation and its failure is a major cause of male infertility. Therefore, a proper model that recapitulates spermatogenesis in vitro...
2.
Tomimoto Y, Yamazaki R, Shirai H
Sci Rep
. 2023 Mar;
13(1):4922.
PMID: 36966210
VHH, the antigen-binding fragment of a heavy chain-only antibody, is a useful component of antibody-based therapeutics. Thermal stability, represented by the melting temperature (Tm), is one of the key factors...
3.
Yoshida K, Kuroda D, Kiyoshi M, Nakakido M, Nagatoishi S, Soga S, et al.
Sci Rep
. 2019 Mar;
9(1):4482.
PMID: 30872635
Antibodies protect organisms from a huge variety of foreign antigens. Antibody diversity originates from both genetic and structural levels. Antigen recognition relies on complementarity between antigen-antibody interfaces. Recent methodological advances...
4.
Yagi M, Palacpac N, Ito K, Oishi Y, Itagaki S, Balikagala B, et al.
Sci Rep
. 2016 Oct;
6:34363.
PMID: 27703240
The malaria vaccine BK-SE36 is a recombinant protein (SE36) based on the Honduras 1 serine repeat antigen-5 of Plasmodium falciparum, adsorbed to aluminium hydroxide gel. The phase Ib trial in...
5.
Osawa K, Shigemura K, Shirai H, Kato A, Okuya Y, Jikimoto T, et al.
Southeast Asian J Trop Med Public Health
. 2016 Feb;
46(4):720-7.
PMID: 26867392
Abstract. Ribosomal DNA (rDNA) sequences are widely used for phylogenetic and bacterial identification. However, rDNA of different species often reveals similar or identical same sequences. This study employed the bacterial...
6.
Shirai H, Prades C, Vita R, Marcatili P, Popovic B, Xu J, et al.
Biochim Biophys Acta
. 2014 Aug;
1844(11):2002-2015.
PMID: 25110827
More and more antibody therapeutics are being approved every year, mainly due to their high efficacy and antigen selectivity. However, it is still difficult to identify the antigen, and thereby...
7.
Yamashita K, Ikeda K, Amada K, Liang S, Tsuchiya Y, Nakamura H, et al.
Bioinformatics
. 2014 Jul;
30(22):3279-80.
PMID: 25064566
Motivation: Kotai Antibody Builder is a Web service for tertiary structural modeling of antibody variable regions. It consists of three main steps: hybrid template selection by sequence alignment and canonical...
8.
Palacpac N, Ntege E, Balikagala B, Yeka A, Shirai H, Suzuki N, et al.
Int J Environ Res Public Health
. 2014 May;
11(5):4870-85.
PMID: 24806194
Reference intervals for common hematological and clinical chemistry parameters constitute an important basis for health care. Moreover, with increasing priority in drug and vaccine development for infectious diseases in Africa,...
9.
Shirai H, Ikeda K, Yamashita K, Tsuchiya Y, Sarmiento J, Liang S, et al.
Proteins
. 2014 Apr;
82(8):1624-35.
PMID: 24756852
In the second antibody modeling assessment, we used a semiautomated template-based structure modeling approach for 11 blinded antibody variable region (Fv) targets. The structural modeling method involved several steps, including...
10.
Kiyoshi M, Caaveiro J, Miura E, Nagatoishi S, Nakakido M, Soga S, et al.
PLoS One
. 2014 Jan;
9(1):e87099.
PMID: 24475232
The optimization of antibodies is a desirable goal towards the development of better therapeutic strategies. The antibody 11K2 was previously developed as a therapeutic tool for inflammatory diseases, and displays...